Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Short Interest Update

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 27,297 shares, a decline of 47.6% from the February 12th total of 52,048 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 29,595 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily volume of 29,595 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.2% of the company’s stock are short sold.

Hedge Funds Weigh In On Radiopharm Theranostics

Institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. purchased a new position in shares of Radiopharm Theranostics in the second quarter worth approximately $37,000. Marex Group plc purchased a new stake in Radiopharm Theranostics during the fourth quarter valued at approximately $54,000. Virtu Financial LLC bought a new position in Radiopharm Theranostics in the fourth quarter worth approximately $76,000. Finally, Jane Street Group LLC bought a new position in Radiopharm Theranostics in the fourth quarter worth approximately $76,000.

Wall Street Analysts Forecast Growth

RADX has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Thursday, January 22nd. B. Riley Financial restated a “buy” rating and issued a $16.00 price objective (up from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Finally, Wall Street Zen downgraded Radiopharm Theranostics to a “strong sell” rating in a research note on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $15.33.

Radiopharm Theranostics Price Performance

NASDAQ RADX opened at $4.95 on Thursday. Radiopharm Theranostics has a 1-year low of $3.50 and a 1-year high of $16.25. The business’s fifty day moving average price is $4.99 and its 200-day moving average price is $5.36.

Radiopharm Theranostics (NASDAQ:RADX) last posted its quarterly earnings data on Wednesday, January 28th. The company reported ($1.58) EPS for the quarter. The company had revenue of $0.46 million during the quarter.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.